NXgenPort is pioneering the integration of remote physiological monitoring into standard cancer care. Their innovative “smart port” is an implantable vascular access device that combines drug delivery with continuous at-home monitoring of critical health metrics, such as white blood cell counts, vitals, and heart function. This real-time data could empower physicians to proactively manage chemotherapy patients, aiming to reduce the risk of life-threatening complications and hospitalizations. Founded in 2021 by Cathy Skinner and Dr. Rosanne Welcher, NXgenPort leverages company-owned patented technology and partnerships with leading institutions, including Mayo Clinic. With its focus on improving patient outcomes and lowering healthcare costs, NXgenPort is set to redefine the standard of care in cancer treatment.
MILESTONESSeries Seed |
TARGET CANCERSPan Cancer |
FOCUS SECTORScreening, Diagnostics & Monitoring |
WHY WE INVESTED
We invested in NXgenPort because of its potential to revolutionize cancer care through innovative technology. By integrating real-time remote monitoring with a proven implantable port design, NXgenPort aims to address critical gaps in managing chemotherapy for patients and their physicians. Detecting life-threatening conditions early could reduce hospitalizations, and improve treatment outcomes aligns with CANCER FUND’s mission to advance impactful innovations. We believe the experienced team, strong intellectual property, and strategic partnerships position NXgenPort for significant clinical and commercial success.